Status:
COMPLETED
68Ga-P16-093 and 18F-FDG PET/CT Imaging in the Same Group of Clear Cell Renal Cell Carcinoma Patients
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Clear Cell Renal Cell Carcinoma
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
PSMA is highly expressed on the cell surface of the microvasculature of several solid tumors, including clear cell renal cell carcinoma (ccRCC). This makes it a potentially imaging target for the dete...
Detailed Description
Renal cell carcinoma (RCC) is the most common solid tumor within the kidney and accounts for approximately 3% of all malignancies in the world. Clear cell RCC (ccRCC) is the most common subtype and ac...
Eligibility Criteria
Inclusion
- patients with confirmed or suspected clear cell Renal cell carcinoma;
- 68Ga-P16-093 18F-FDG PET/CT within a week;
- signed written consent.
Exclusion
- pregnancy;
- breastfeeding;
- known allergy against PSMA;
- any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Key Trial Info
Start Date :
April 14 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 15 2022
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT05432947
Start Date
April 14 2022
End Date
September 15 2022
Last Update
November 3 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730